Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H8O3 |
| Molecular Weight | 152.1473 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H](C(O)=O)C1=CC=CC=C1
InChI
InChIKey=IWYDHOAUDWTVEP-SSDOTTSWSA-N
InChI=1S/C8H8O3/c9-7(8(10)11)6-4-2-1-3-5-6/h1-5,7,9H,(H,10,11)/t7-/m1/s1
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28936681 | https://www.ncbi.nlm.nih.gov/pubmed/21910908 | http://eci2012.net/wp-content/uploads/2015/03/Mandelamine-PM-En-100446.02-11Mar2015.pdf
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28936681 | https://www.ncbi.nlm.nih.gov/pubmed/21910908 | http://eci2012.net/wp-content/uploads/2015/03/Mandelamine-PM-En-100446.02-11Mar2015.pdf
(R)-Mandelic acid (D-Mandelic acid) is an enantiomer of the aromatic alpha hydroxy acid that is used as a chiral resolving agent, and as a building block to synthesize pharmaceutical drugs such as penicillin and cephalosporin. (R)-(-)-Mandelic acid, is used as an antiseptic ingredient particularly against urinary tract infections.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL335 |
5500.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Mandelamine Approved UseFor the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis and other urinary tract infections. |
Sample Use Guides
500 mg (R/S-Mandelic acid) - 2 tablets 4 times a day (in the form of (Methenamine Mandelate Tablets U.S.P.).
Route of Administration:
Oral
Antimicrobal activity of mandelic acid was determined by disc diffusion method. S. aureus type strains (ATCC 700698 and ATCC 25923) and 19 isolates were incubated with 10 ul of 160, 80, 40, 30, 20 and 10 mg/ml of the acid. Concentrations required to inhibit 50 and 90% of the clinical isolates (MIC50 and MIC90) were 20 and 40 (mg/ml) respectively and those required to kill 50 and 90% of the strains (MBC50 and MBC90) were 20 and 80 (mg/ml) respectively.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
PPL7YW1M9W
Created by
admin on Sat Dec 16 07:58:27 GMT 2023 , Edited by admin on Sat Dec 16 07:58:27 GMT 2023
|
PRIMARY | |||
|
DB02280
Created by
admin on Sat Dec 16 07:58:27 GMT 2023 , Edited by admin on Sat Dec 16 07:58:27 GMT 2023
|
PRIMARY | |||
|
11914
Created by
admin on Sat Dec 16 07:58:27 GMT 2023 , Edited by admin on Sat Dec 16 07:58:27 GMT 2023
|
PRIMARY | |||
|
210-276-6
Created by
admin on Sat Dec 16 07:58:27 GMT 2023 , Edited by admin on Sat Dec 16 07:58:27 GMT 2023
|
PRIMARY | |||
|
DTXSID4046523
Created by
admin on Sat Dec 16 07:58:27 GMT 2023 , Edited by admin on Sat Dec 16 07:58:27 GMT 2023
|
PRIMARY | |||
|
17656
Created by
admin on Sat Dec 16 07:58:27 GMT 2023 , Edited by admin on Sat Dec 16 07:58:27 GMT 2023
|
PRIMARY | |||
|
611-71-2
Created by
admin on Sat Dec 16 07:58:27 GMT 2023 , Edited by admin on Sat Dec 16 07:58:27 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
